Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q1 2026 revenue around $205M, full-year guidance raised to about $925M total global revenue, BRIUMVI execution remains strong, and technical momentum is favorable with about 16% 21-day gain and 17% in the last 5 sessions.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Earnings Compression ⢠Rising Debt TGTX offers strong liquidity, high gross margins, and improving quarterly cash flow, but sharply lower earnings, rising leverage, and richer valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Strong rebound ⢠Resistance test ⢠Support holding Support Level: $53.00â$54.00 Resistance Level: $56.90 TGTX is technically bullish over the last month, but a decisive break above $56.90 is needed to confirm upside while $53.00â$54.00 remains key support.
Sentiment & News
Key News Insights: ⢠BRIUMVI Share Gains ⢠Raised Revenue Outlook ⢠Pipeline Catalysts TG Therapeutics' rising BRIUMVI market share, increased revenue outlook, pipeline catalysts, and institutional buying support a bullish outlook, though buyout speculation remains unconfirmed.
AI Summary
TGTX has evolved into a BRIUMVI commercial-execution story with credible upside if share gains translate into operating leverage, but its ~$8.5B valuation leaves little room for a repeat of weak profit conversion, rising debt costs, or any slowdown in its single-product franchise.
Description
TG Therapeutics is a commercial-stage biopharmaceutical company that develops and commercializes therapies for Bâcell malignancies and certain autoimmune disorders. Its pipeline combines monoclonal antibodies and oral small-molecule inhibitorsâtargeting Bâcell receptors and immune checkpointsâalongside early-stage programs in epigenetics and immune signaling, supported by multiple licensing and collaboration agreements with international partners. The company was incorporated in 1993 and is headquartered in New York, NY.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| May 6 | May 13 | TGTX | TG Therapeutics, Inc. | Q1 2026 revenue around $205M, full-year guidance raised to about $925M total global revenue, BRIUMVI execution remains strong, and technical momentum is favorable with about 16% 21-day gain and 17% in the last 5 sessions. | Closed | +1.6% |